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1. Introduction 
1.1. The peritoneal cavity, locoregional area 
The peritoneal cavity, enclosed by visceral and parietal peritoneum , is the largest potential 
space in the body. With its own vascularization and lymphatic drainage, is anatomically 
separated from the general body system and other body compartments. 
 
Figure 1. Mechanisms of peritoneal cancer cells seeding. 
Any pathological process involving the peritoneal cavity can easily disseminate throughout 
this space by means of unrestricted movement of fluid and cells. Accordingly malignant 
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intraperitoneal tumour progression, before reaching the circulation system and developing 
distant metastases (pulmonary, brain and bone metastases) diffuses within and through the 
peritoneal cavity (Fig. 1). At this step intraperitoneal tumours must be considered in 
locoregional stage. 
Peritoneal neoplasia can originate de novo from the peritoneal tissues (primary tumour) or 
invade or metastasize into the peritoneum from adjacent or remote organs (metastases). 
Rare are the primitive tumours of the peritoneum: they include malignant mesothelioma, 
peritoneal primary carcinoma and sarcoma. 
Malignant peritoneal mesothelioma is a rare but aggressive tumor derived from the 
peritoneal mesothelium accounting for 2 cases per 1 million population reported each year 
in USA. Association of malignant peritoneal mesothelioma and asbestos exposure has been 
reported to be as high as 83%. This locally aggressive disease is difficult to treat or palliate. 
Commonly, treatment regimens combine aggressive cytoreductive surgery with 
intraperitoneal chemotherapy. Cytoreductive surgery is the cornerstone of current 
treatment, while hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) is a 
promising strategy in suitable patients (Deraco et al., 2002) (Fig. 2). 
 
Figure 2. Omental cake. 
Primary peritoneal carcinoma is a very rare tumour and (ie, serous surface papillary 
carcinoma) arises primarily from peritoneal cells. This malignancy predominantly affects 
postmenopausal women and typically displays multicentric peritoneal and omental 
involvement. Pathologically and clinically, it resembles papillary serous ovarian carcinoma. 
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Many primary tumours, arising from organs placed within the peritoneal cavity, 
disseminate through it, leading patients to death. Peritoneal cavity represents the site of 
metastases in 50% of colorectal cancer, 50% of gastric cancer and 75% of ovarian advanced 
cancer. It represents the sole site of intraperitoneal metastasis in 20-25% of colorectal cancer, 
30% of gastric cancer and 70% of ovarian cancer (Koppe et al., 2006; Randall and Rubin, 2001; 
Sadeghi et al., 2000). Intraperitoneal drug administration studies confirmed the existence of a 
peritoneal-plasma barrier which allows to concentrate the antiblastic drug within the cavity 
even 100-1000 times compared with that of the same drug infused through systemic 
circulation. Therefore a high antiblastic tumour tissue concentration and a low systemic 
toxicity can be achieved (Flessner, 2005). In association with intraperitoneal chemotherapy, 
hyperthermia has been demonstrated to enhance drug diffusion within the tumour tissue 
and also to have a direct antitumour activity (Issels, 2008) (Fig. 3) 
 
Figure 3. Hyperthermia effects on tumour cells. 
Therefore cytoreduction and HIPEC procedure have been suggested to treat metastases 
from colorectal , gastric and gynaecological tumors (Sugarbaker, 1995). Results after 
treatment are encouraging in particular in cases of colorectal and gynaecological cancer with 
median 5 years survival respectively of 40% and 45%. Less satisfactory results have been 
obtained in case of gastric and pancreatic cancer with a minimal percentage of patient still 
living far from initial diagnosis (Elias et al., 2006; Roviello et al., 2011). The aggressive 
tumour surgical removal (tumour cytoreduction) coupled with intraperitoneal 
chemotherapy nowadays represents the cornerstone of advanced abdominal oncologic 
surgery (Glehen et al., 2006; Glockzin et al., 2009). A large international experience was 
therefore made through the last decades with the goal of allowing treatment and possibly 
cure of intraperitoneal tumours in advanced stage (Levine et al., 2007; Roviello et al., 2011). 
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Figure 4. Peritoneal cancer index to map carcinosis localization. 
2. Cytoreduction and intraperitoneal hyperthermic chemotherapy 
(HIPEC) 
Advanced metastatic tumour can therefore be treated with surgery and hyperthermic 
chemotherapy contemporarily, during the same surgical operating work up. The first step is 
to carry out an aggressive cytoreduction in order to remove the whole macroscopic 
intracavitary tumour tissue and then to complete the procedure with HIPEC, to kill residual 
neoplastic cells floating within the peritoneal cavity or adherent to intraperitoneal tissue. 
2.1. Cytoreduction 
The surgical procedure of cytoreduction is now well standardized . Sugarbaker’s 
classification is still the reference for abdominal oncologic surgery and goes under the 
definition of peritonectomy. The surgical procedure was classified according to specific 
different areas of the abdominal cavity and it has been tailored by Milan ‘s panel workshop, 
defining (Fig. 4): 
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Figure 5. Surgical cytoreduction. 
1. Upper RightPeritonectomy: right diaphragmatic peritonectomy with Glisson’s capsule 
dissection; lesser omentectomy, stripping of the omental bursa and cholecystectomy 
plus gastric antrectomy or total gastrectomy. 
2. Upper Left Peritonectomy: left diaphragmatic and parietal peritonectomy with 
splenectomy and greater omentectomy. 
3. Pelvic Peritonectomy: pelvic parietal peritonectomy, sigmoidectomy, hysterectomy and 
salpingo-ovariectomy. 
4. Right Parietal Peritonectomy, right/total colectomy; left parietal peritonectomy. 
5. Mesenteric implants on visceral surfaces could be removed surgically or by 
electrosurgical local dissection. Performing cytoreduction for peritoneal tumour 
dissemination, not all the procedures are necessary and made, usually necessitating one 
– three of the different peritonectomy procedures (Fig. 4 and 5). 
2.2. Intraperitoneal hyperthermic chemotherapy 
After having made complete surgical cytoreduction with an absent or minimal residual 
disease (less than 2.5 mm tumour diameter) some catheters are inserted into the abdominal 
cavity and a perfusion of 2 liters of a saline solution with a determined quantity of 
antiblastic drug (Mytomycin, Oxaliplatin for digestive cancer and Cisplatin, Taxol for 
ovarian cancer) is made . The peritoneal perfusion may lasts 30-90 minutes and it can be 
performed in condition of closed abdomen or open abdomen (Coliseum technique) or a 
compromise between the two, with an abdominal- wall small entrance suitable for the 
handling by the operator. (Fig. 6). 
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Figure 6. Hyperthermic intraperitoneal chemotherapy 
Hyperthermic perfusion can be obtained by heating the perfusion medium with a heat 
exchanger connected to the perfusion pump. The peritoneal cavity temperature considered 
optimal in terms of antitumor activity and antiblastic tumour tissue diffusion is 41,5-42,5 °C 
(Sugarbaker and Chang, 1999; Sugarbaker, 1996; Van der Speeten et al., 2009). It is of 
absolute importance to control the temperature of organs and bowels during the procedure. 
Excessive temperature of intraperitoneal tissue, more than 43 °C, is strongly correlated with 
lesions of the bowel wall and perforation, and also with necrosis of nerves, bladder or vases. 
To prevent excessive intraperitoneal temperature multiple temperature probes are placed 
within the peritoneal cavity to monitorate the temperature. At the end of the procedure the 
perfused medium is usually removed from the peritoneal cavity. 
3. Advanced oncological surgery in colorectal cancer 
Every year about 400.000 new cases of colorectal cancer (CRC) are diagnosed in Europe and 
210.000 are believed to die of disease (Boyle and Ferlay, 2005). Peritoneal carcinosis (PC) has 
an incidence about 13% of CRC, in 58% of cases is synchronus with primary disease and in 
most cases is not diffused to the entire abdominal cavity but limited to an area (Jayne et al., 
2002). Peritoneal cavity recurrence is the only site of relapse in about 25% of cases (Chu et al., 
1989). The principal mechanism of peritoneal cancer diffusion through the abdominal cavity 
is the esfoliation of cancer cells following bowel-serosa tumour infiltration. Also lymphatic 
channel infiltration by the tumour followed by breaking of the lymphatic channel wall and 
subsequently loss of neoplastic cells within the abdominal cavity is a mechanism of PC 
formation. Furthermore at the time of surgical work up tumour manipulation and blood loss 
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are also intracavitary mechanism of PC formation. Facing PC, both synchronous or 
metachronous, the usual treatment is systemic chemotherapy but median survival is usually 
not longer than 6 months even after the advent of new drugs and treatment scheme 
(Sadeghi et al., 2000). More recently Dominique Elias has published an experience with 
patients with PC and absence of extra-abdominal disease by using modern scheme of 
chemotherapy FOLFOX (5-FU, AF and oxaliplatin) and FOLFIRI (5-FU, AF and irinotecan) 
obtaining a median survival of 23,9 months and a 2 and 5 years survival of 65% and 13% 
respectively (Elias et al., 2009). The advent of CRS with HIPEC have ameliorated the 
prognosis in these patients (Elias et al., 2006; Verwaal et al., 2005; Yan and Morris, 2008). 
During the last decade a randomized study , two multicentric comparative studies and a 
numbers of observational studies have tested the CRS and HIPEC activity against PC from 
CRC with encouraging results: mortality and postoperative morbidity of 0-8% and 39-72% 
respectively and 5 years survival of 40-51% (Verwaal et al., 2003, 2005; Elias et al., 2009, 2006; 
Franko et al., 2010). Main indications for application of the procedure are the presence of PC 
both synchronous or metachronous , therefore defining it a therapeutic procedure. But 
recent experiences also suggest the possible use of HIPEC in adjuvant setting after radical 
surgery work up. Not all patients with CRC could benefits from this approach. A number of 
risk factors for PC development have been demonstrated: minimal PC which was 
macroscopically visible, completely resected or ovarian metastasis (also resected), 
synchronous with the primary tumour or a perforated primary tumor inside the peritoneal 
cavity, primary CRC presenting with occlusion or haemorrhagia. Patients bearing these risk 
factors and treated with cytoreduction and HIPEC at the end of cytoreduction (no residual 
tumour disease was present - R0 resection) showed, in preliminary experiences, impressive 
results with a 5 years survival percentage reaching 90% and a 5 years disease free survival of 
more than 40% (Elias et al., 2009). This preliminary experience supports a large number of 
multi-istitutional ongoing worldwide studies to confirm the role of cytoreduction and 
hyperthermic intraperitoneal chemoperfusion in adjuvant setting at the same time of 
primary surgery or after a planned second look exploration. This new therapeutic approach 
even if after a long maturation phase lasting more than a decade, now seems to be accepted 
as a new frontier to treat advanced CRC and world wide surgical units have been created to 
coordinate and carry on the associated medical activity. 
4. Advanced oncological surgery in gastric cancer 
PC from gastric cancer arises following tumours invasion of the gastric serosa as depicted in 
Fig. 7. Also histological type can be crucial in PC gastric developing. Gastric tumours of the 
diffused type seems to represent a risk factor for PC and it has been demonstrated to relapse 
in about 50% of cases even after curative surgical resection (Marrelli et al., 2002). It has been 
shown that the serosal tumor invasion is correlated to the detection rate of intraperitoneal 
free cancer cells. The treatment of peritoneal carcinomatosis from gastric cancer by 
peritonectomy and HIPEC has demonstrated not so good long-term results when compared 
with the treatment of PC from other causes (Stewart et al., 2005). Anyway conventional 
treatment using palliative systemic chemotherapy showed a very dismal prognosis 
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(Hanazaki et al., 1999). Long survival after peritonectomy and HIPEC for carcinomatosis 
arising from gastric cancer are possible if the extension of the carcinosis is low and the 
cytoreduction is complete. 3-year survival of 41% and 5-year survival rates of 11% was 
reported (Sayag-Beaujard et al., 1999; Yonemura et al., 2001, 1996). CRS and HIPEC of the PC 
seems to allow longer survival even if hyperthermic intraperitoneal chemoperfusion role is 
still under evaluation. 
 
Figure 7. Invasion of the gastric serosa. 
Recent experiences with HIPEC have shown quite encouraging results in case of prevention 
of peritoneal recurrence after radical surgery for primary carcinoma, the adjuvant role. 
When curative gastrectomy is performed, in fact, peritoneal recurrence develops in nearly 
50% of patients , therefore prevention of PC developing represent a fundamental goal in this 
setting (Yonemura et al., 2001, 1996; Fujimoto et al., 1999; Shen et al., 2009). Worldwide 
experiences are ongoing to ascertain the role of HIPEC in adjuvant setting and definitive 
results will be available in a short time. 
5. Advanced oncological surgery in ovarian cancer 
Epithelial ovarian cancers account for 80% to 90% of all ovarian malignancies and are the 
main cause of death for all gynaecological tumors (Yancik, 1993). Despite being diagnosed 
frequently at an advanced stage, dissemination is often confined to the peritoneal cavity 
(Randall and Rubin, 2001). It presents with vague gastrointestinal and constitutional 
symptoms of abdominal bloating, distension, weight loss, and fatigue (Goff et al., 2000). Late 
presentation results in the majority of patients being diagnosed with advanced disease 
(Stage III/IV). The 5-year survival rate of patients with advanced ovarian cancer is <25% 
(Ozols, 2005). In the final stages of this disease, patients suffer from severe anorexia, 
dyspnea and pain from malignant bowel obstruction, ascites, and pleural effusion as a result 
of the extensive burden of tumor. 
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Epithelial ovarian tumor arises from the serosal lining of the ovary. This covering of the 
ovary communicates with the serosal lining of the abdominopelvic cavity, and is known as 
the peritoneum. Tumor growth results in the exfoliation of malignant cells into the 
peritoneal fluid. They circulate freely and typically implant in the pelvis and 
subdiaphramatic recesses owing to gravity and the incumbent position. Intraoperatively, it 
is characterized by the extensive presence of macroscopic whitish tumor nodules of variable 
sizes and consistency that may coalesce to form plaques or masses within the 
abdominopelvic cavity. 
Tumor dissemination from the primary tumour may also occur through the lymphatic 
channel disrupted by the tumour and the direction of neoplastic cell diffusion is all through 
the abdominal cavity. 
CRS using limited peritonectomy procedures to resect peritoneal implants and HIPEC aims 
to allow both macroscopic cytoreduction through surgery and cytotoxic cytoreduction 
through loco-regional administration of heated chemotherapy. Cytoreduction and HIPEC 
has been tested in different routes; front line when treating the primary cancer, as interval 
surgery after neoadjuvat chemotherapy in case of unresectable cancer, as treatment of 
ovarian cancer relapses and even in case of salvage therapy (Look et al., 2004). 
 
Figure 8. Ovarian cancer survival in compete and non complete cytoreduction. 
The largest experience to date was reported by Bereder who reported a median overall 
survival of 46 months in patients with first relapsed ovarian cancer of which a proportion 
are chemoresistant. In their institutions, the mortality rate was under 1% and the morbidity 
rates were about 10%.The treatment related complications is considered acceptable and 
further large volume peritonectomy units have low morality rates that range from 0 to 2% 
(Raspagliesi et al., 2006; Bereder et al., 2009; Look et al., 2004). Nowadays there is large 
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agreement on the role of extreme cytoreduction of peritoneal carcinosis in case of ovarian 
cancer. Two groups of patients are then obtained: those with residual disease no more than 
2.5 mm in diameter corresponding to the completeness cytoreduction rate CC0-1 and those 
with residual disease more than 2.5 mm CC2-3. The first group with a complete tumour 
eradication shows a significative better survival (Fig. 8). 
Promising results have been published during this decade improving survival and disease 
free survival. This particular indication for this complex procedure represents a very 
promising but also conflicting tool because of the high drug Platinum sensitivity of ovarian 
cancer which makes medical oncologist to be confident with systemic chemotherapy results. 
Unfortunately despite a great number of patients optimally treated in this way a significant 
fraction of them relapse (50-70%) and in this case it is reasonable to think that extreme 
cytoreduction and HIPEC can be helpful. 
6. Advanced oncological surgery in malignant peritoneal mesothelioma 
Diffuse malignant peritoneal mesothelioma (DMPM) is a relatively uncommon peritoneal 
malignancy, representing 20-30% of 2.200-2.500 new cases diagnosed every year in USA, but 
its incidence has been rising worldwide since 1970s and is not expected to peak for another 5 
to 20 years. The reason lays in its recognized association with asbestos exposure, which has 
been extensively used in the past as building material (Battifora, 1995; Robinson and Lake, 
2005). Along with the occupational exposure, DMPM has been reported following radiation 
therapy, mica exposure, recurrent peritonitis and thorium dioxide administration (Maurer 
and Egloff, 1975; Antman et al., 1983; Chahinian et al., 1982; Riddell et al., 1981). 
It is characterized macroscopically by thousands of whitish tumor nodules of variable size 
and consistency that may coalesce to form plaques or masses that may layer out to 
uniformly cover the entire peritoneal surface. Traditionally, DMPM was considered a 
preterminal condition, as the majority of patients died from intestinal obstruction or 
terminal starvation within the first year from the diagnosis (Yan et al., 2007). Despite its 
generally local spread without lymphoadenopathy or distant organ metastases, its poor 
prognosis may be explained by late diagnosis, due to the aspecificity of presenting 
symptoms (abdominal pain, girth, ascitis,...) and the inadequateness of most imaging tools 
in detecting small nodules on the whole peritoneal surface. Furthermore, no uniform 
treatment was initially suggested for this kind of malignancy, systemic chemotherapy and 
abdominal radiation therapy showed scarce results and were used only in selected patients, 
and surgery had only a palliative role to resolve intestinal obstruction in urgency without 
any significant effect on patients prognosis (Chailleux et al., 1988; Antman et al., 1983; 
Eltabbakh et al., 1999; Markman and Kelsen, 1992; Neumann et al., 1999; Sridhar et al., 1992; 
Yates et al., 1997). Recently, diagnostic and therapeutic aspects of the disease have been re-
evaluated as encouraging reports from several centers worldwide on a combined 
locoregional treatment approach that uses cytoreductive surgery (CRS) and hyperthermic 
intraperitoneal chemotherapy (HIPEC) have emerged. This new treatment strategy has 
shown favorable prognosis and has achieved in selected patients a median survival of up to 
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60 months and a 5-year survival of 50% using different antiblastic sequence (Deraco et al., 
2006; Nonaka et al., 2005; Park et al., 1999; Sugarbaker et al., 2003; Yan et al., 2007). 
Given its tendency to remain confined to the peritoneal surface, the prognosis of DMPM has 
been significantly improved by the combined treatment with CRS and HIPEC. In particular, 
while CRS reduces the tumoral mass (an optimal cytoreduction aims to residual disease 
smaller than 2,5mm), HIPEC maximizes loco-regional chemotherapy cytotoxicity while 
limiting the systemic side effects (Vlasveld et al., 1991; Markman, 1990; Markman and 
Kelsen, 1992). In this perspective, some encouraging experiences in numerous centers 
demonstrated a median survival of 40 to 90 months and a 5-ys-OS of 30 to 60% (Yan et al., 
2007; Brigand et al., 2006; Deraco et al., 2006; Feldman et al., 2003; Loggie et al., 2001; Nonaka 
et al., 2005; Park et al., 1999; Sugarbaker et al., 2003). All peritonetomy center agree that 
complete cytoreduction is the prognostic principal factor for clinical success and that 
complete cytoreduction is correlated to the initial extent of intrabdominal disease and to the 
ability of the surgical team. Despite the data available, the role of HIPEC in this setting 
represents one of the strongest indications, particularly in view of considerable survival 
improvement over the best systemic therapy to date offered (Munkholm-Larsen et al., 2009; 
Shen et al., 2009). 
7. Advanced oncological surgery in pseudomyxoma peritonei 
Appendiceal tumors are uncommon neoplasms accounting for about 1% of all colorectal 
malignancies. 
The majority of appendix cancers are carcinoid tumors; the second most common are 
epithelial neoplasms. The latter frequently present with mucinous ascites and mucinous 
tumor implants throughout the abdominal cavity. Such rare condition, with an incidence of 
approximately 1/1,000,000/year, is known as pseudomyxoma peritonei (PMP). Mucinous 
adenocarcinoma originating from large bowel, ovary, or other intra-abdominal sites may 
mimic PMP (Baratti et al., 2008). According to Ronnett, PMP was histologically classified 
into disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis 
(PMCA), and intermediate or discordant feature group (ID). Appendiceal tumors were 
classified into low-grade appendiceal mucinous neoplasm (LAMN) and mucinous 
adenocarcinoma (MACA) (Misdraji). Pseudomyxoma peritonei (PMP) represents a rare 
peritoneal malignancy with a controversial bordeline behavior. Although a possible ovarian 
origin was initially suggested in the female sex, the over-expression of determined 
molecular markers has finally demonstrated a more probable PMP origin from a perforated 
appendiceal epithelial tumor. Undoubtedly, a small proportion of cases originate anyway 
from other organs, which ovarian primary is likely to be the more commonest of, followed 
by colon and rectum, stomach, gallbladder and biliary ducts, small bowel, urinary bladder, 
lung, breast, falloppian tube and pancreas (Smeenk et al., 2006, 2007; de Bree et al., 2000). 
PMP is clinically characterized by diffuse intra-abdominal gelatinous collections with 
mucinous implants on peritoneal surfaces. Its pathognomonic accumulation at specific 
abdominal and pelvic sites is due to the so-called phenomenon of “redistribution” within 
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the peritoneal cavity, which is determined by physical factors, such as the movement and 
absorption of peritoneal fluid and gravity (Sugarbaker, 1994). Despite its usually indolent 
behavior, its natural history is characterized by a slow progression to terminal starvation 
through intestinal obstruction by mucinous ascitis. Recent pathological (Ronnett et al., 1995) 
molecular genetic (Szych et al., 1999) and immunohistochemical studies (Carr et al., 2002) 
have provided substantial evidence that most cases of PMP originate from ruptured low 
grade appendiceal tumors and that mucin-producing epithelial cells accumulate into the 
abdominal cavity as a result of a distribution process.Therefore, surgical management 
consisted in repeated interval debulking for symptomatic relief (Sugarbaker, 1996). Based on 
recent prospective trials, CRS and HIPEC has been proposed as the standard of care for 
PMP. Results are encouraging with a 5-ys-OS ranging from 62.5 to 100% for low grade PMP 
and from 0 to 65% for high grade disease . This differentiation is crucial for the evolution of 
disease; low grade tumours are slow growing and indolent differently from those high 
grade, fast growing and aggressive (Sugarbaker and Chang, 1999; Witkamp et al., 2001; 
Güner et al., 2005; Moran et al., 2008; Moran and Cecil, 2003; Murphy et al., 2007; Baratti et al., 
2008; Elias et al., 2008; Loungnarath et al., 2005; Smeenk et al., 2007; Stewart et al., 2005; Yan 
et al., 2006). The goal of the surgical cytoreduction is to remove all the visible tumor by the 
following procedures: right subdiaphragmatic and parietal peritonectomy, left 
subdiaphragmatic and parietal peritonectomy,greater omentectomy with splenectomy, 
lesser omentectomy and stripping of the omental bursa, andpelvic peritonectomy with 
salpingo-oophorectomy in women. Depending on disease extent, implants on visceral 
serosa were removed by electrosurgical local dissection or multivisceral resections including 
Glisson’s capsule dissection, cholecystectomy, partial or total gastrectomy, sigmoid, right or 
total colectomy. According to several phase I and II prospective trials, 5-year survivals have 
ranged between 66% and 97% (Stewart et al., 2005). It must be taken in mind that, because of 
the limited data on prognostic factors for this procedure in the setting of appendiceal 
primary tumors, further well designed, prospective, multi-institutional study are required 
(Bevan et al., 2010; Roviello et al., 2011). 
8. Conclusion 
CRS and HIPEC is a complex therapeutic systems which require highly specialized human 
resources, complex technological facilities, very much depending from expertize of the team 
involved. Literature refers to a learning curve of more than 100 procedures underscoring the 
crucial importance of treatment center experience. A continuous comparison must be done 
with new systemic and locoregional treatment possibility in order to verify new advantages 
in term of patient survival. This is the reason why a biannual international meeting is 
planned for comparing results, verify indications and planning of further studies regard to 
indications, duration and temperature of the perfusion, open or closed perfusion models or 
type and dosage of chemotherapeutic agents. 
The future of treatment of peritoneal carcinosis appears correlated to the strong cooperation 
with medical oncologists to select patients and focusing on the timing of treatment which in 
our experience is crucial. The development of new scheme treatment must be approached as 
in treating ovarian peritoneal carcinosis with front line, interval, or salvage procedures. 
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Therefore creating regional centers dedicated to peritoneal carcinosis treatment that 
investigate not only response and survival, but also standardization of technique and 
methods to do CRS and deliver HIPEC remains crucial. 
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